BACKGROUND AND OBJECTIVES: Chronic pain and psychiatric disorders are common in dialysis patients, but the extent to which opioids and benzodiazepines are used is unclear. We conducted a systematic review to determine the: (1) prevalence of opioid and benzodiazepine use among dialysis patients; (2) reasons for use; (3) effectiveness of symptom control; and (4) incidence of adverse events. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Two authors reviewed all relevant citations in MEDLINE/EMBASE/CINAHL/BIOSIS Previews/Cochrane and hand-searched bibliographies. Studies after 1990 reporting prevalence estimates for opioid and/or benzodiazepine use in ≥50 dialysis patients were included. RESULTS: We identified 15 studies from 12 countries over 1995 to 2006. Sample size ranged from 75 to 12,782. Prevalence of opioid and benzodiazepine use was variable, ranging from 5 to 36% (95% CI, 4.1 to 45.5%; n=10) and 8 to 26% (95% CI, 7.1 to 27.3%; n=9), respectively. Prevalence was positively correlated with years on dialysis. Five studies reported on the same cohorts but gave different prevalence estimates. One study verified medication use through patient interviews. Reasons for use were reported in one study. Effectiveness of pain control varied from 17 to 38%, and 72 to 84% of patients with significant pain had no analgesia (n=2). No study rigorously examined for adverse events. CONCLUSIONS: The prevalence of opioid and benzodiazepine use in dialysis patients is highly variable between centers. Further information is needed regarding the appropriateness of these prescriptions, adequacy of symptom control, and incidence of adverse effects in this population.
BACKGROUND AND OBJECTIVES: Chronic pain and psychiatric disorders are common in dialysis patients, but the extent to which opioids and benzodiazepines are used is unclear. We conducted a systematic review to determine the: (1) prevalence of opioid and benzodiazepine use among dialysis patients; (2) reasons for use; (3) effectiveness of symptom control; and (4) incidence of adverse events. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Two authors reviewed all relevant citations in MEDLINE/EMBASE/CINAHL/BIOSIS Previews/Cochrane and hand-searched bibliographies. Studies after 1990 reporting prevalence estimates for opioid and/or benzodiazepine use in ≥50 dialysis patients were included. RESULTS: We identified 15 studies from 12 countries over 1995 to 2006. Sample size ranged from 75 to 12,782. Prevalence of opioid and benzodiazepine use was variable, ranging from 5 to 36% (95% CI, 4.1 to 45.5%; n=10) and 8 to 26% (95% CI, 7.1 to 27.3%; n=9), respectively. Prevalence was positively correlated with years on dialysis. Five studies reported on the same cohorts but gave different prevalence estimates. One study verified medication use through patient interviews. Reasons for use were reported in one study. Effectiveness of pain control varied from 17 to 38%, and 72 to 84% of patients with significant pain had no analgesia (n=2). No study rigorously examined for adverse events. CONCLUSIONS: The prevalence of opioid and benzodiazepine use in dialysis patients is highly variable between centers. Further information is needed regarding the appropriateness of these prescriptions, adequacy of symptom control, and incidence of adverse effects in this population.
Authors: Steven D Weisbord; Anne Marie Shields; Maria K Mor; Mary Ann Sevick; Marcia Homer; Janet Peternel; Patricia Porter; Bruce L Rollman; Paul M Palevsky; Robert M Arnold; Michael J Fine Journal: Contemp Clin Trials Date: 2010-07-01 Impact factor: 2.226
Authors: George R Bailie; Stacey J Elder; Nancy A Mason; Yasushi Asano; Jose M Cruz; Shunichi Fukuhara; Antonio A Lopes; Donna L Mapes; David C Mendelssohn; Juergen Bommer; Eric W Young Journal: Nephrol Dial Transplant Date: 2007-02-01 Impact factor: 5.992
Authors: George R Bailie; Nancy A Mason; Jennifer L Bragg-Gresham; Brenda W Gillespie; Eric W Young Journal: Kidney Int Date: 2004-06 Impact factor: 10.612
Authors: Stacey J Elder; Ronald L Pisoni; Tadao Akizawa; Rachel Fissell; Vittorio E Andreucci; Shunichi Fukuhara; Kiyoshi Kurokawa; Hugh C Rayner; Anna L Furniss; Friedrich K Port; Rajiv Saran Journal: Nephrol Dial Transplant Date: 2007-10-01 Impact factor: 5.992
Authors: Julie H Ishida; Charles E McCulloch; Michael A Steinman; Barbara A Grimes; Kirsten L Johansen Journal: J Am Soc Nephrol Date: 2018-09-21 Impact factor: 10.121
Authors: Janette Baird; Mark Faul; Traci C Green; Jonathan Howland; Charles A Adams; Melinda J Hodne; Nie Bohlen; Michael J Mello Journal: J Trauma Nurs Date: 2019 May/Jun Impact factor: 1.010
Authors: Min Zhan; Rebecca M Doerfler; Dawei Xie; Jing Chen; Hsiang-Yu Chen; Clarissa J Diamantidis; Mahboob Rahman; Ana C Ricardo; James Sondheimer; Louise Strauss; Lee-Ann Wagner; Matthew R Weir; Jeffrey C Fink Journal: Am J Kidney Dis Date: 2020-04-18 Impact factor: 8.860
Authors: Julie H Ishida; Charles E McCulloch; Michael A Steinman; Barbara A Grimes; Kirsten L Johansen Journal: Clin J Am Soc Nephrol Date: 2018-04-19 Impact factor: 8.237
Authors: Matthew Daubresse; G Caleb Alexander; Deidra C Crews; Dorry L Segev; Mara A McAdams-DeMarco Journal: Am J Nephrol Date: 2018-12-13 Impact factor: 3.754
Authors: Ngan N Lam; Mark A Schnitzler; David A Axelrod; Huiling Xiao; Mara McAdams-DeMarco; Dorry L Segev; Allan B Massie; Vikas R Dharnidharka; Abhijit S Naik; Abimereki D Muzaale; Gregory P Hess; Bertram L Kasiske; Krista L Lentine Journal: Clin Transplant Date: 2020-08-03 Impact factor: 2.863